Analyst consensus rating
Nurix Therapeutics Analyst Rating: Strong Buy
NRIX is rated Strong Buy by 16 analysts with a $33.50 target. As of 2026-08-18.
Direct answer
Nurix Therapeutics's consensus rating is Strong Buy.
16 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $33.50.
Forecast evidence checked August 18, 2026.
Get free Nurix Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $27.17
- Average price target
- $33.50
- High price target
- $45.00
- Low price target
- $25.00
- Low target gap
- -8%
- Target upside
- +23.3%
- High target gap
- +65.6%
- Target range width
- 73.6%
- Consensus rating
- Strong Buy
- Analysts
- 16
- Evidence date
- August 18, 2026
- Valid through
- August 25, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Nurix Therapeutics?
Nurix Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $33.50.
How far are Nurix Therapeutics's low and high targets from the recorded price?
The low target implies -8%, while the high target implies +65.6%.
How many analysts are included in Nurix Therapeutics's consensus?
The verified consensus includes 16 analysts.
How is Nurix Therapeutics's target upside or downside calculated?
The average target of $33.50 is divided by the recorded price of $27.17, then one is subtracted to produce +23.3%. This does not guarantee a future return.
When was Nurix Therapeutics's analyst forecast verified?
The data was verified on 2026-08-18. The dataset is valid through 2026-08-25.